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StructureA recent study with ﬂaviviruses suggested that structural dynamics of the virion impact antibody neutraliza-
tion via exposure of ostensibly cryptic epitopes. To determine whether this holds true for the distantly related
hepatitis C virus (HCV), whose neutralizing epitopes may be obscured by a glycan shield, apolipoprotein in-
teractions, and the hypervariable region on the E2 envelope protein, we assessed how time and temperature
of pre-incubation altered monoclonal antibody (MAb) neutralization of HCV. Notably, several MAbs showed
increased inhibitory activity when pre-binding was performed at 37 °C or after longer pre-incubation pe-
riods, and a corresponding loss-of-neutralization was observed when pre-binding was performed at 4 °C. A
similar proﬁle of changes was observed with acute and chronic phase sera from HCV-infected patients. Our
data suggest that time and temperature of incubation modulate epitope exposure on the conformational en-
sembles of HCV virions and thus, alter the potency of antibody neutralization.
© 2011 Elsevier Inc. All rights reserved.Introduction
Hepatitis C virus (HCV) is a hepatotropic virus that chronically infects
~170 million people worldwide and results in an increased risk of hepa-
tocellular carcinoma and liver cirrhosis. Until recently, the only available
treatmentwas a combined regimenof ribavirin andpegylated interferon-
α, which resulted in sustained virologic response in only ~50% of individ-
uals (Bowen and Walker, 2005). The addition of newly approved NS3
protease inhibitors (boceprevir and telaprevir) to this regimen has im-
proved response rates, although an increase in side effects was noted
(Bacon et al., 2011; Jacobson et al., 2011; Poordad et al., 2011; Zeuzem
et al., 2011). Given that long-term pharmacological therapy may have
limitations in curing HCV-infected individuals, especially in resource-
poor settings, there is renewed interest in the development of preventa-
tive or even therapeutic vaccines (Strickland et al., 2008). Vaccine devel-
opment, however, has been hampered by the absence of a tractable small
animal model of HCV infection and an incomplete understanding of the
correlates of antibody protection in vivo., Molecular Microbiology, and
l of Medicine, 660 South Euclid
4 362 9230.
iamond).
rights reserved.HCV is a positive stranded 9.6 Kb RNA virus in the Hepacivirus
genus of the Flaviviridae family, which also includes globally impor-
tant pathogens such as Dengue (DENV), West Nile (WNV), yellow
fever, and Japanese encephalitis viruses (Lindebach et al., 2007).
HCV is translated from an internal ribosome entry site (IRES) as a sin-
gle polyprotein and is cleaved by viral and host proteases into three
structural (core, E1, E2) proteins, the ion channel p7, and six non-
structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B)
(Lindenbach and Rice, 2005). Cell culture-produced HCV forms
smooth, spherical, enveloped particles that are ~60 nm in diameter
(Gastaminza et al., 2010; Yu et al., 2007) with E1 and E2 on the sur-
face. Despite recent predictive models suggesting that HCV E2 protein
assumes a three domain structure similar to the E protein of ﬂavi-
viruses (Krey et al., 2010), E2 is distinguished from ﬂavivirus E pro-
tein by its nine intramolecular disulﬁde bonds (Krey et al., 2010),
covalent linkage to E1 (Vieyres et al., 2010), 11 N-linked glycosylation
sites (Goffard et al., 2005; Goffard and Dubuisson, 2003), and two hy-
pervariable regions (HVR1 and HVR2) (McCaffrey et al., 2007;Weiner
et al., 1991). E2 contains binding sites for both the CD81 and SR-B1
receptors (Pileri et al., 1998; Scarselli et al., 2002), and MAbs that
block CD81-E2 and SR-B1-E2 interactions prevent infection in cell
culture (Bartosch et al., 2003; Hadlock et al., 2000; Law et al., 2008;
Owsianka et al., 2001, 2008; Sabo et al., 2011; Tarr et al., 2006).
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remains controversial, although several studies have suggested that
anti-E2 antibodies can limit infection in vivo (Farci et al., 1996;
Houghton and Abrignani, 2005; Law et al., 2008). Antibodies elicited
by immunization of chimpanzees with HCV envelope proteins partially
protect against viral challenge (Forns et al., 2000; Meunier et al., 2011;
Puig et al., 2004). In the setting of acute infection in humans, antibody
responses against the HCV envelope proteins are delayed, with less
than 33% of subjects developing neutralizing antibodies at six months
(Netski et al., 2005). Many humans generate a neutralizing antibody re-
sponse that correlates with viral clearance although chronically infected
patients also produce neutralizing antibodies (Logvinoff et al., 2004).
Thus, the presence of neutralizing antibodies in serum does not directly
correlatewith a viral clearance phenotype. Possible explanations for this
phenomenon include: (i) HCV E2 interactionwith high-density lipopro-
teins (HDL) shields virions from recognition by neutralizing antibodies
that are present in serum (Bartosch et al., 2005; Dreux et al., 2006;
Lavillette et al., 2005), (ii) different functional classes of neutralizing an-
tibodies have distinct inhibitory mechanisms and potencies or (iii) im-
mune pressure drives rapid viral escape from the host humoral
response (Dowd et al., 2009; von Hahn et al., 2007).
Antibody-mediated neutralization of Flaviviridae family members
requires engagement by antibodies with a stoichiometry that exceeds
a particular threshold (reviewed by (Dowd et al., 2011)). The number
of antibodies bound to the virus particle is governed by the avidity of
the antibody for its cognate epitope on the virion and the number of
times that epitope is displayed accessibly on the virion. Antibody
avidity determines the fraction of accessible epitopes bound by anti-
body molecules at a given concentration of antibody (Dowd and
Pierson, 2011; Klasse and Sattentau, 2002). For ﬂaviviruses (e.g.,
WNV), the envelope proteins are arranged with T=3 quasi-
icosahedral symmetry on the virion surface and displayed in three
distinct environments deﬁned by their proximity to the 2-, 3-, or 5-
fold axis of symmetry. Because of this, the minimum occupancy re-
quirement for neutralization by a given antibody may never be
achieved (reviewed in (Diamond et al., 2008)). Despite this, MAbs
that bind to epitopes that are predicted to be cryptic can still neutral-
ize infection (Lok et al., 2008; Oliphant et al., 2006; Stiasny et al.,
2006). Recent studies with WNV and DENV have demonstrated that
cryptic epitopes can become exposed with increased antibody-virus
pre-incubation time or temperature, presumably due to enhanced
viral motion (Dowd et al., 2011).
Although HCV E2 is predicted to have a structure similar to ﬂavivi-
rus E proteins (Krey et al., 2010), the organization of the HCV virion
and exposure of speciﬁc epitopes under conditions of dynamic mo-
tion remains unclear. Furthermore, the association of the HCV with
apolipoproteins (Meunier et al., 2008; Owen et al., 2009), the glycan
shield, and additional intramolecular and intermolecular disulﬁde
linkages on E2 also could impose limits on epitope accessibility. To
gain more insight into the variation of epitope exposure on the sur-
face of HCV, we studied the effects of temperature and time of
antibody-virus incubation on neutralization of HCV using a previously
characterized panel of MAbs (Sabo et al., 2011).
Results
Temperature alters the neutralization potency of anti-E2 MAbs
Studies with distantly related ﬂaviviruses have suggested that virus
“breathing” occurswith increased temperature allowing differential ex-
posure of epitopes and altered antibody binding and neutralization
(Dowd et al., 2011; Lok et al., 2008). As HCV envelope proteins have a
greater number (9 versus 6) of intramolecular disulﬁde bonds (Gubler
et al., 2007; Krey et al., 2010), which could rigidify the structure, we ini-
tially assessed whether temperature changes altered infectivity of an
H77/JFH1 chimeric HCV. A one hour incubation at 4 °C, 37 °C, 40 °Cand 43 °C had relatively small (~2-fold) effects on HCV infectivity
(Fig. 1A). To assess how temperature alteredMAb-mediated neutraliza-
tion, serial dilutions of two previously described neutralizing anti-E2
MAbs, H77.39 and J6.36 (Sabo et al., 2011) were incubated with a geno-
type 2a J6/JFH1/Jc1 luciferase reporter virus (Sabo et al., 2011) for one
hour at 4 °C, 37 °C, or 40 °C. To ensure that only the pre-incubation tem-
perature was being evaluated, virus-MAb mixtures subsequently were
bound to cells at 4 °C, and unbound virus and MAb was washed away
prior to raising the temperature to 37 °C for infection. Neutralization
by H77.39 and J6.36 was abolished at 4 °C and improved at 40 °C
(Figs. 1B and C). Comparison of the EC50 values at 37 °C and 40 °C
also was statistically different (Figs. 1B and C, right panels, Pb0.03). As
expected, neutralization of HCV infection was not observed at 4 °C,
37 °C, or 40 °C with the negative control MAb (WNV-E16), which
binds to WNV E protein (data not shown). The effects of temperature
on MAb neutralization could not be attributed to virus aggregation, as
enhanced neutralization at higher temperatures also was observed
with FAb fragments (Fig. 1D), and the neutralization curves did not
show a characteristic triphasic curve that is reported in studies describ-
ing antibody-virus aggregation (Thomas et al., 1986). Of note, and in
contrast to experiments with intact IgG, we omitted the wash step in
FAb fragment neutralization assays prior to HCV infection, as washing
resulted in a complete loss of inhibitory activity, likely secondary to
the loss of avidity and resulting detachment of FAb fragments from
the virion (data not shown). Thus, excess FAb fragments were present
beyond the initial incubation (at 4 °C or 40 °C) period and throughout
the experiment (at 37 °C), which explainswhy the 4 °C condition inhib-
ited infection as opposed to that observed with intact H77.39 IgG
(Fig. 1B).
MAb-virus but not E2 binding is reduced at lower temperatures
To assess whether the temperature-dependent difference in MAb
neutralization of HCV reﬂected a change in afﬁnity, the KD of antibody
interaction with soluble E2 ectodomain (sE2) was measured at 4 °C
and 37 °C by surface plasmon resonance (SPR). Monovalent afﬁnities
were calculated using steady-state analysis between genotype 1a
(H77) and genotype 2a (J6) sE2 and H77.39, and genotype 2a (J6)
sE2 and J6.36. Notably, the KD values were not substantially different
at 4 °C and 37 °C (Table 1). As no appreciable dissociation was ob-
served between sE2 and immobilized H77.39 and J6.36 MAb, kinetic
parameters were not deﬁned although a qualitative assessment indi-
cated extremely long half-lives at both temperatures (Figs. 2A and B).
These data suggest that the altered MAb neutralization proﬁles at dif-
ferent temperatures were not due to large-scale effects on E2 binding.
Consistent with this, prolonged pre-incubation periods at 4 °C up to
24 h only partially restored neutralization by H77.39 and J6.36
(Fig. 2C), and did not alter infectivity of the J6/JFH1/Jc1 luciferase re-
porter virus in the absence of MAb (Fig. 2D). In comparison, pre-
incubation of cells at 4 °C for one hour with anti-CD81 MAb efﬁciently
neutralized HCV infection (Fig. 2C).
We hypothesized that the greater MAb neutralization potency at
higher temperatures was due to enhanced epitope exposure and cap-
ture. To test whether temperature affected the physical interaction of
HCV virions with MAbs, immunoprecipitation studies were per-
formed. J6/JFH1/Jc1 virus was pre-incubated with J6.36 MAb at 4 °C,
37 °C, or 40 °C for one hour, virus-MAb complexes were immunopre-
cipitated with protein G Sepharose, and levels of viral RNA were ana-
lyzed by qRT-PCR. As expected, in all cases, greater amounts of HCV
were immunoprecipitated by J6.36 MAb than the negative control
WNV-E16 MAb (Fig. 3), establishing the speciﬁcity of the assay. Sig-
niﬁcantly more virus was precipitated when the pre-binding step
was performed at 37 °C or 40 °C compared to 4 °C (Fig. 3, Pb0.01).
Despite the enhanced MAb neutralization at 40 °C relative to 37 °C
(see Fig. 1), we did not observe a statistical difference (P>0.2) in
virus precipitated by J6.36 MAb after pre-binding at 37 °C compared
Fig. 1. Temperature alters the neutralizing capabilities of anti-E2 MAbs. A. Chimeric H77/JFH1 HCV was incubated for one hour at the speciﬁed temperatures, added to Huh7.5 cells,
the temperature raised to 37 °C, and infectivity assessed 72 h later by FFU assay. Results of FFU assays are pooled from three independent experiments performed in triplicate. As-
terisks represent statistically signiﬁcant differences in infectivity: *, Pb0.05; **, Pb0.01; and ***, Pb0.001. B–D. Serial dilutions of (B) H77.39 MAb, (C) J6.36 MAb, or (D) H77.39 FAb
fragments were pre-incubated with J6/JFH1/Jc1 luciferase reporter virus for one hour at either 4 °C (♦), 37 °C (●) or 40 °C (■). For B and C, MAb-virus mixtures were incubated at
the indicated temperature, chilled, and then added to pre-chilled Huh7.5 cells to allow for attachment. Cells were then washed thrice (removing excess virus and antibody) and the
temperature raised to 37 °C for the duration of the assay. For D, FAb-virus mixtures were incubated at the indicated temperature and then added to pre-chilled Huh7.5 cells to allow
for attachment. Infectivity was assessed by luciferase assay 48 h later. Dose response curves (left panels) are displayed relative to the infectivity of HCV pre-incubated at the indi-
cated temperature in the absence of antibody. Comparison by F-test demonstrated a statistically signiﬁcant difference between the curves in all cases (Pb0.001). The EC50 values at
37 °C and 40 °C (right panels) were determined by nonlinear regression analysis and asterisks represent signiﬁcant differences: *, Pb0.05; **, Pb0.01; and ***, Pb0.001. Graphs are
pooled from at least three independent experiments performed in duplicate. Error bars represent the standard error of the mean.
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Table 1
Kinetic parameters of MAb binding to sE2 at different temperatures.
KD (4 °C) KD (37 °C) Fold difference
H77.39-H77 E2 (1a) 1.66×10−7 4.69×10−8 3.54
H77.39-J6 E2 (2a) 2.50×10−7 4.84×10−8 5.17
J36-J6 E2 (2a) 4.25×10−8 8.91×10−9 4.77
Estimates of the KD were determined by equilibrium binding ﬁts of E2 to H77.39 and
J6.36 at 4 °C and 37 °C degrees. Fold difference was calculated by dividing the KD
determined for each MAb-E2 pair at 4 °C by the KD determined at 37 °C.
Fig. 3. Changes in temperature alter MAb-virus binding. J6/JFH1/Jc1 luciferase reporter
virus was pre-incubated for one hour at 4 °C (white bars), 37 °C (gray bars), or 40 °C
(black bars) with J6.36 MAb, a negative control MAb (WNV-E16) or medium alone,
precipitated with protein G Sepharose beads, and the quantity of virus was assessed
by qRT-PCR. Data are pooled from at least three independent experiments performed
in duplicate. Fold change is calculated compared to viral RNA detected in the absence
of antibody. Asterisks represent statistically signiﬁcant differences: *, Pb0.05;
**, Pb0.01; and ***, Pb0.001. Error bars represent the standard error of the mean.
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stability of virus at 40 °C, which is not accounted for in this
experiment.
Increased incubation time at 37 °C enhances MAb-virus binding and
neutralization
Increasing the pre-incubation period also can enhance MAb potency,
possibly due to changes in epitope accessibility as the virus samples alter-
nate ensembles of conformations over time (Dowd et al., 2011). To assess
whether longer incubation times augmentedMAb neutralization of HCV,
serial dilutions of H77.39 and J6.36 MAbs were incubated for one hour at
37 °C to achieve baseline equilibrium binding, and MAb-virus mixtures
were either added immediately to Huh7.5 cells (time 0) or incubated
for an additional 2, 4 or 8 h prior to infection. Increasing the pre-
incubation period consistently improved neutralization potencyFig. 2.MAb-E2 binding kinetics are not altered by changes in temperature. A–B. SPR analysis of
graphs of the steady-stateﬁt of E2 binding toH77.39 at 4 °C (A) and37 °C (B) are shown. Points
represents the steady-state ﬁt of themaximumRU values. C. Effect of time of incubation at 4 °C
WNV-E16 (negative control)) were incubated with J6/JFH1/Jc1 luciferase reporter virus at 4 °C
additional 12 (T=12, black bars) or 24 h (T=24, gray bars) at 4 °C prior to infection. Cells the
unbound virus, the temperaturewas raised to 37 °C, and infectivity detected by luciferase assay
pooled from three independent experiments performed in duplicate. Asterisks represent statis
tibody at the speciﬁed time point: *, Pb0.05; **, Pb0.01; and ***, Pb0.001. D. Effect of time of in
was incubated at 4 °C for one hour (T=0) or an additional 12 (T=12) or 24 h (T=24). Infecti
periments performed in triplicate. Infectivity is not signiﬁcantly different at T=12 and T=24(Figs. 4A and B), with a signiﬁcant reduction in EC50 values occurring
after 8 h of pre-incubation (Figs. 4C andD, Pb0.05). To determinewheth-
er this effect was due to enhanced MAb-virus binding, complexes wereMAb binding to soluble E2 at different temperatures. Examples of sensograms (inset) and
representmaximumresonance units (RU) at various concentrations of E2 and the solid line
onMAb neutralization. MAbs (50 μg/ml of H77.39, J6.36, anti-CD81 (positive control) and
for one hour and added directly to Huh7.5 cells (T=0, white bars), or incubated for an
n were infected with MAb-virus complexes for one hour at 4 °C, washed at 4 °C to remove
48 h later. Infectivity is displayed relative to conditions in the absence ofMAb. Graphs are
tically signiﬁcant differences in infectivity compared to cells infected in the absence of an-
cubation at 4 °C on infectivity in the absence of MAb. J6/JFH1/Jc1 luciferase reporter virus
vity is expressed as relative light units (RLU). Data are pooled from three independent ex-
compared to T=0. Error bars represent the standard error of the mean.
178 M.C. Sabo et al. / Virology 422 (2012) 174–184formed for up to 8 h prior to immunoprecipitation, and viral RNA was
quantiﬁed by qRT-PCR. Notably, the amount of virus precipitated was in-
creased after 2, 4 and 8 h of additional pre-incubation at 37 °C (Fig. 4E,
Pb0.05).
Increased incubation time and temperature broadly improves antibody
function against HCV
MAbs J6.36 and H77.39 were mapped previously to residues with-
in and adjacent to the hypervariable region 1 (HVR1) on the E2 pro-
tein (Sabo et al., 2011). To determine whether temperature andFig. 4. Incubation time alters MAb neutralization and binding to HCV. A–D. Neutralization a
ciferase reporter virus for one hour at 37 °C to achieve a baseline equilibrium. Samples were
(T=2, □), 4 (T=4, Δ), or 8 (T=8, ●) hours at 37 °C prior to infection of cells. Infectivity w
different (F-test, Pb0.0001) and are displayed relative to the infectivity of HCV incubated fo
J6.36 at each time point were determined by non-linear regression analysis. Asterisks repres
***, Pb0.001. E. Immunoprecipitation assays. J6.36 and J6/JFH1/Jc1 virus were pre-incubate
beads were added immediately (T=0) or at 2, 4, and 8 h (T=2, 4 and 8, respectively) and
background binding of virus to beads alone. Asterisks represent signiﬁcant differences
**, Pb0.01; and ***, Pb0.001. Graphs are pooled from at least three independent experimentime-dependent effects also altered neutralization of MAbs mapping
to different sites with distinct potencies, we tested a panel of neutral-
izing and non-neutralizing MAbs for functional changes with in-
creased pre-incubation temperature (40 °C) or time (12 h) (Fig. 5).
The most potent of the additional MAbs tested, H77.16, localizes to
residues in the HVR1 (G406, N410, I411) and the CD81 binding region
(G530) (Sabo et al., 2011), and showed enhanced neutralization with
changes in temperature and time during pre-incubation. This im-
proved activity was reﬂected by a shift in neutralization curves (F
test, Pb0.0001) and EC50 values (unpaired t-test, Pb0.01) (Fig. 5A).
In comparison, the more weakly neutralizing MAbs J6.27 andnalysis. Serial dilutions of (A) H77.39 or (B) J6.36 were incubated with J6/JFH1/Jc1 lu-
added either immediately to Huh7.5 cells (time 0, ■) or incubated for an additional 2
as determined by luciferase expression 48 h later. Dose response curves are statistically
r the indicated time interval in the absence of MAb. EC50 values of (C) H77.39 and (D)
ent signiﬁcant differences in EC50 values compared to T=0: *, Pb0.05; **, Pb0.01; and
d for one hour at 37 °C to achieve baseline equilibrium binding. Protein G Sepharose
bound virus was quantitated by qRT-PCR. Fold change was determined compared to
in fold change in virus precipitated at T=0 compared to other times: *, Pb0.05;
ts performed in duplicate and error bars represent the standard error of the mean.
Fig. 5. The effects of increased incubation time and temperature on additional neutralizing and non-neutralizing MAbs. Serial dilutions of additional puriﬁed (A) strongly, (B) weak-
ly, or (C) non-neutralizing MAbs were incubated with either J6/JFH1/Jc1 reporter virus (J6.103) or H77/JFH1 virus (H77.16, H77.31, H77.46, J6.27) for one hour at 37 °C or 40 °C.
Virus-MAb mixtures were then immediately added to cells (T=0) or incubated for an additional 12 h (T=12) at 37 °C prior to infection of cells. Dose response curves are displayed
relative to the infectivity of HCV in the absence of antibody for each of the conditions tested and represented by the following symbols: ■, T=0 h, 37 °C; ▼, T=0 h, 40 °C; ▲,
T=12 h, 37 °C. Graphs are pooled from at least three independent experiments performed in duplicate. Error bars represent the standard error of the mean. Asterisks represent
signiﬁcant differences in the EC50 value compared to that at time 0, 37 °C: *, Pb0.05; **, Pb0.01; and ***, Pb0.001.
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Fig. 6. Kinetic and temperature-dependent enhancement of neutralization by sera from HCV infected patients. A. Acute or chronic phase sera from HCV infected patients (S154,
S112, S18 and S19) or control sera (SM) was serially diluted and incubated with H77/JFH1 chimeric virus for one hour at 37 °C or 40 °C. Sera-virus complexes were added to
pre-seeded Huh7.5 cells (T=0) or incubated for an additional 12 h at 37 °C prior to infection of cells (T=12). Infectivity was assessed by FFU assay 72 h post-infection. Comparison
of dose response curves by F test demonstrated a signiﬁcant difference (Pb0.0001) in neutralization under different conditions with S154, S112, S18 and S19 sera, but not with
negative control serum (SM). Dose response curves are displayed relative to the infectivity of HCV in the absence of antibody for each of the conditions tested and represented
by the following symbols: ■, T=0 h, 37 °C; ▼, T=0 h, 40 °C; ▲, T=12 h, 37 °C. Graphs are pooled from at least three independent experiments performed in duplicate and
error bars represent the standard error of the mean. B. Chronic phase sera from HCV infected patients (H06, AA) or control sera (SM) was serially diluted and incubated with ge-
notype 2a J6/JFH1/Jc1 luciferase reporter virus for one hour at 37 °C or 40 °C. Sera-virus complexes were then added directly to Huh7.5 cell monolayers (T=0) or incubated for an
additional 12 h at 37 °C prior to infection of cells (T=12). Infectivity was assessed by luciferase expression 48 h post-infection. Comparison of dose response curves by F test dem-
onstrated a signiﬁcant difference (Pb0.0001) in neutralization under different conditions by H06 and AA, but not by negative control sera (SM).
180 M.C. Sabo et al. / Virology 422 (2012) 174–184H77.31, which map to residues in the CD81 binding region, or J6.103,
which maps to the HVR1 and the intergenotypic variable region (Krey
et al., 2010; McCaffrey et al., 2007; Sabo et al., 2011), showed little en-
hancement of neutralization under the conditions tested (Fig. 5B,
P>0.2). The only non-neutralizing MAb tested showing improved
neutralization with increased temperature or time was H77.46
(Fig. 5C, Pb0.001).
Neutralization potency of immune sera from HCV-infected patients is im-
proved by incubation at higher temperature and prolonged time
To further assess the relevance of increased temperature or incu-
bation time on antibody neutralization, we analyzed its impact on
polyclonal antibody from sera from acute or chronically HCV-infected patients. Enhanced neutralization of HCV was observed
after pre-incubation at 40 °C for one hour or 37 °C for 12 h with sera
from patients acutely infected with genotype 1 (S154) or chronically
infected with genotype 1 (S112, S18, S19, H06) and genotype 4 (AA)
(Figs. 6A and B, Pb0.0001, F test). However, sera from several of the
patients (S154, S112, S18 and S19) infected with genotype 1 failed
to cross-neutralize the genotype 2 HCV strain, indicating the inhibito-
ry effect was antigen-speciﬁc (data not shown). Also, as expected, no
speciﬁc increase in neutralization with time or temperature change
was observed with sera from an uninfected individual (SM). Thus,
polyclonal anti-HCV antibody present in immune sera behaved in a
manner similar to MAbs of deﬁned speciﬁcity with respect to the ef-
fects on neutralization of prolonged time or elevated temperature
exposure.
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Prior studies with distantly related ﬂaviviruses have established
that antibody-mediated neutralization of infection is modulated by
several factors including avidity of binding and the availability of
the epitope on the virion surface (reviewed in (Diamond et al.,
2008; Pierson et al., 2007)). Nonetheless, some antibodies neutralize
infection despite binding epitopes that ostensibly are obscured on
the virion, at least based on contemporary high-resolution structural
models (Dowd et al., 2011; Lewis et al., 1998; Li et al., 1994; Lok et al.,
2008). This has led to the concept of virus “breathing” in which struc-
tural perturbations on the virion surface allow antibody to bind cryp-
tic epitopes, a phenomenon that can be promoted by changes in
temperature (Dowd et al., 2011; Li et al., 1994; Lok et al., 2008) and
time of interaction (Dowd et al., 2011; Ruprecht et al., 2011). Al-
though it is closely related to ﬂaviviruses, it was unclear whether sim-
ilar principles apply, as HCV contains additional intramolecular and
intermolecular cysteine bonds on its envelope proteins that could re-
strict motion and exposure of hidden epitopes. Indeed, unlike ﬂavi-
viruses, HCV is resistant to inactivation at low pH in solution and
does not undergo plasma membrane fusion from without (Tscherne
et al., 2006). These observations may be explained by recent evidence
suggesting covalent linkage between the glycoproteins on the virion
surface (Vieyres et al., 2010), a feature that would affect structural
protein packing, limit viral breathing, and impact transient exposure
of some epitopes. Nonetheless, in our study, we showed that increas-
ing the time and temperature of pre-incubation enhanced neutraliza-
tion of HCV by monoclonal and polyclonal antibodies, suggesting that
epitope accessibility can change in a manner analogous to that ob-
served with ﬂaviviruses.
Cryo-electron microscopy studies with the related DENV demon-
strated that incubation of virions at physiological temperature (37 °C)
induced alterations in the virion icosahedral structure (Lok et al.,
2008) that expose cryptic epitopes allowing for antibody binding and
neutralization (Dowd et al., 2011). In the absence of high-resolution
structural information on the HCV envelope proteins or virions, we
assessed functionally whether changes in temperature impacted HCV
stability or antibody neutralization, presumably by altering epitope ac-
cessibility. As prolonged incubation in solution over a range of temper-
atures (4° to 43 °C) only minimally impacted infectivity (see also
(Ciesek et al., 2010; Kim et al., 2011)), HCV appears relatively stable,
suggesting it does not readily undergo irreversible structural changes.
Consistent with this, and in direct contrast to the related ﬂaviviruses,
HCV can be stored at 4 °C for several weeks without appreciable loss
of infectivity (Ciesek et al., 2010) and exposure to a pH 5.0 acidic solu-
tion does not expose domains on the envelope proteins that result in
adventitious fusion and virus inactivation (Tscherne et al., 2006). None-
theless, prolonged time and elevated temperature likely promoted
changes in the ensemble of virion conformations, as signiﬁcantly differ-
ent neutralization proﬁles were observed with some but not all anti-
HCV antibodies. The changes in neutralization at different temperatures
reﬂect altered epitope exposure and notmodiﬁed binding kinetics or vi-
rion aggregation, as SPR experiments showed minimal change in afﬁn-
ity between 4 °C and 37 °C and neutralization by monovalent FAb
fragments ofHCV antibodies alsowas enhanced at higher temperatures.
Together, with our immunoprecipitation experiments showing that in-
creased amounts of virus are precipitated at 37 °C compared to 4 °C,
these data suggest that HCV undergoes some structural perturbations
over time, which results in altered epitope capture and antibody
neutralization.
The CD81-binding site on HCV E2 may be shielded by HVR1 and a
subset of N-linked glycans (N417, N423, N448, and N532), as deletion
of HVR1 or site-speciﬁc substitutions that abolish N-liked glycosyla-
tion sites augments the inhibitory capacity of antibodies disrupting
E2-CD81 interactions (Bankwitz et al., 2010; Helle et al., 2010). Be-
cause of this, we anticipated that increasing the time and temperatureof interaction would facilitate exposure of antibody epitopes proxi-
mal to the CD81 binding site region, resulting in improved neutraliz-
ing activity. While we observed enhanced potency of neutralization
by MAbs (H77.16, H77.39 and J6.36) mapping to HVR1 or contiguous
regions, we did not observe this effect for weakly neutralizing MAbs
(H77.31 and J6.27) that localize to the CD81 binding region. The fail-
ure to observe enhanced inhibitory activity by E2-speciﬁc MAbs that
interfere with CD81 binding may reﬂect a requirement for more sig-
niﬁcant structural shifts for complete epitope exposure, analogous
to the those required to reveal the CCR5 binding epitope on HIV
gp120 (Kwong et al., 1998; Rizzuto et al., 1998). Indeed, previous
studies have demonstrated that anti-CD81 antibodies inhibit infec-
tion at a post-attachment step, indicating that CD81 is not completely
engaged by the virus directly after attachment (Bertaux and Dragic,
2006; Haberstroh et al., 2008; Sabo et al., 2011). Interestingly, the
MAb J6.103 also did not demonstrate enhanced potency, despite
mapping to the same residues as a MAb that did, J6.36 (Sabo et al.,
2011), possibly due to variations in the MAb footprint that are not ap-
parent from our epitope mapping by yeast surface display; indeed,
J6.36 and J6.103 have different receptor-blocking capabilities (Sabo
et al., 2011), suggesting these MAbs are not functionally equivalent.
While many humans develop a neutralizing antibody response that
correlates with viral clearance, chronically infected patients also pro-
duce neutralizing antibodies (Logvinoff et al., 2004). Thus, the presence
of neutralizing antibodies in serum does not directly correlate with a
viral clearance phenotype. Our studies show that elevated temperature
modulates the potency of neutralizing anti-HCV antibodies, a ﬁnding
thatmay have implications for an improved understanding of the corre-
lates of antibody protection for HCV: (i) the inherent neutralizing ca-
pacity of antibody in serum could change substantially depending on
assay conditions; and (ii) fever occurs as a collateral effect of therapy
with pro-inﬂammatory pegylated IFN-α (Zeuzem et al., 2000). It is
tempting to speculate that the fever response associated with therapy
could improve the efﬁciency of antibody neutralization.
Generation of a vaccine for HCV in part, has been hampered by the
lack of a structural understanding of the virus. Although direct struc-
tural studies of the HCV virion are required to corroborate our ﬁnd-
ings, our studies suggest that HCV has a dynamic component
analogous to ﬂaviviruses (Dowd et al., 2011; Lok et al., 2008). None-
theless, portions of the CD81 binding region on E2 likely remain
shielded, making this region a challenge for molecular and immuno-
logical targeting. Further study and identiﬁcation of the host factors
that modulate antibody neutralization against HCV will likely inform
strategies to contain and control infection through induction of more
potently inhibitory humoral responses.
Materials and methods
Cells and viruses
Huh7.5 cells were cultured as previously described (Sabo et al.,
2011). Virus stocks of the HJ3-5 H77/JFH1 chimeric virus and the lu-
ciferase expressing J6/JFH1/Jc1 virus were generated as described
(Sabo et al., 2011) and concentrated using Amicon Ultra tubes
(Milipore) with 100 kDa cut-off membranes.
Quantitative RT-PCR
RNA was extracted using the RNA Easy Mini kit (Qiagen). qRT-PCR
was performed using the Taq-Man one-step RT-PCR master mix re-
agents (Applied Biosystems) and the following primers and probe lo-
cated in the 3′ untranslated region (3′ UTR): Forward primer: 5′-GGC
TCC ATC TTA GCC CTA GTC-3′; Reverse primer: 5′-AGT ATC GGC ACT
CTC TGC AGT-3′; and probe 6FAM5′-CGG CTC ACG GAC CTT TCA CAG
CT3′. Data was analyzed using a 7500 Fast Real-Time PCR system (Ap-
plied Biosystems) with 7500 Software (Applied Biosystems, v 2.0.5).
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The anti-E2 MAbs H77.31, H77.39, H77.46, J6.27, J6.36, and J6.103
were described previously (Sabo et al., 2011). The anti-CD81 antibody
(JS-81) was purchased from BD Biosciences. WNV-E16 has been ex-
tensively described (Nybakken et al., 2005; Oliphant et al., 2005).
HCV immune sera from infected patients (AA, H06, S18, S19, S112,
and S154,) have been described previously (Cox et al., 2005; Osburn
et al., 2010; Scheel et al., 2008). Negative control serum (SM) was
obtained from an HCV-naive donor.
Neutralization assays
Neutralization of the chimeric H77/JFH1 virus containing the geno-
type 1 structural proteins was assessed by focus forming unit (FFU) re-
duction assay. Serial three-fold dilutions of antibody were pre-
incubated with 3.2 x 102 FFU of HCV for one hour at 37 °C and added
to a monolayer of Huh7.5 cells in a 96-well plate coated with poly-L
lysine (Sigma). Three days later, cellswere ﬁxedwith ice-coldmethanol
(0 °C) and foci quantiﬁed as previously described (Sabo et al., 2011)
using a S5 Biospot Macroanalyzer (Cellular Technologies Ltd).
Neutralization of the genotype 2 J6/JFH1/Jc1 virus was determined
by luciferase assay as previously described (Sabo et al., 2011). Serial
three-fold dilutions of antibody were pre-incubated with 5×102
FFU of virus for one hour at 37 °C and added to monolayers of
Huh7.5 cells in a 96-well black bottom plate (Corning). Luciferase ex-
pression was detected after 48 h as previously described (Sabo et al.,
2011), according to the manufacturer's instructions.
To assess the role of temperature onMAb activity, neutralization as-
says were modiﬁed as follows. Serial dilutions of antibody were pre-
incubated with HCV (multiplicity of infection (MOI) of 0.05) for one
hour at 4 °C, 37 °C, or 40 °C. In most experiments, antibody-virus mix-
tures were added to monolayers of Huh7.5 cells and infection assessed
as described above. In some experiments with H77.39 and J6.36,
antibody-virus mixtures were chilled, added to pre-chilled monolayers
of Huh7.5 cells, and “spinoculated” at 1500 rpm for 45 min at 4 °C. After
three washes with ice cold DMEM containing 10% FBS, the temperature
was raised to 37 °C, and infectivity assessed by luciferase assay or FFU
assay 48 h or 72 h later, respectively. Relative infectivity was deter-
mined after comparison to infectivity of HCV incubated at the same
temperature in parallel in the absence of antibody.
To assess the role of incubation time on antibody potency, neutral-
ization assays were modiﬁed as follows. Serial dilutions of antibody
were pre-incubated with HCV at an MOI of 0.05 for one hour at
37 °C to achieve baseline neutralization. Antibody-virus mixtures
were then either directly added to monolayers of Huh7.5 cell or incu-
bated for an additional 2, 4 or 8 h prior to infection of cells. Infectivity
was assessed by luciferase assay or FFU assay 48 h or 72 h later, re-
spectively. Relative infectivity was determined after comparison to
infectivity of HCV incubated under the same conditions in parallel
in the absence of antibody.
Immunoprecipitation assays
To assess for changes in MAb-virus binding at different tempera-
tures, 50 μg/ml of J6.36, negative control MAb (WNV-E16) or medium
alone were pre-incubated with 500 FFU of HCV (J6/JFH1/Jc1) for one
hour at 4 °C, 37 °C or 40 °C. Subsequently, 50 μl of protein G Sepharose
(Pierce) was added, and the slurry mixed overnight at 4 °C. Sepharose
beads were pelleted at 1000×g for 2 min and washed six times each
with 1 ml of PBS. Pellets were lysed and RNA was extracted using the
Qiamp viral RNA mini kit (Qiagen) and quantitated by qRT-PCR.
To assess for changes in MAb-virus binding over longer pre-
incubation periods the immunopreciptation assay was modiﬁed as
follows. MAbs J6.36, WNV-E16 or medium alone were pre-
incubated with 500 FFU of virus for one hour at 37 °C and protein GSepharose was then added immediately and MAb-virus slurries
mixed at 4 °C, or MAb-virus mixtures were incubated for an addition-
al 2, 4, or 8 h prior to the addition of protein G Sepharose and transfer
to 4 °C for mixing. Protein G Sepharose beads were pelleted and
washed, and HCV RNA was extracted and quantiﬁed by RT-PCR.
Surface plasmon resonance
Thedissociation constants ofMAbsH77.39 and J6.36 for sE2 fromge-
notypes 1a (H77) and 2a (J6) were determined by surface plasmon res-
onance on a Biacore T100 instrument. Approximately 500 response
units (RU) of H77.39, J6.36 and negative control murine MAb (anti-
H2-Kb) were covalently coupled to a CM5 sensor chip using amine
chemistry. Increasing concentrations of monomeric, soluble E2 (4 to
1024 nM) were ﬂowed over the chip in 10 mMHEPES, 150 mM sodium
chloride, 3 mM EDTA, and 0.005% polysorbate 20 (HBS-EP) at 4 °C and
37 °C. Binding and dissociation phases were each carried out at 40 μl/
min for 180 s and the chip was regenerated with 60-second pulses of
0.1 M acetate pH 4.2 and 1 M sodium chloride. All curveswere reference
subtracted from a ﬂow cell containing the negative control MAb. Maxi-
mum response units were plotted versus concentration and this curve
was ﬁtted to determine KD at each temperature. Antibody J6.36 is not
cross-reactive so its afﬁnity for the genotype 1a sE2was not determined.
Statistical analysis
Data was analyzed using GraphPad Prism software, version 4.0.
Comparison of dose response curves was assessed by an F-test. Viral
co-immunoprecipitation assays and EC50 values were analyzed
using an unpaired t-test.
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